
    
      This is a Phase 2, open-label, randomized 2-arm multicenter study to assess the safety and
      efficacy of STI-5656 (Abivertinib Maleate) administered orally plus Standard of Care (SOC)
      versus SOC in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 infection and COVID-19
      pneumonia (documented radiographically). Only hospitalized patients are eligible for this
      study.
    
  